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Abstract
In DNA methylation microarray analysis, quantitative assessment of intermediate methylation levels
in samples with various global methylation levels is still difﬁcult. Here, speciﬁcally for methylated DNA
immunoprecipitation-CpG island (CGI) microarray analysis, we developed a new output value. The
signal log ratio reﬂected the global methylation levels, but had only moderate linear correlation
(r 5 0.72) with the fraction of DNA molecules immunoprecipitated. By multiplying the signal log
ratio using a coefﬁcient obtained from the probability value that took account of signals in neighbour-
ing probes, its linearity was markedly improved (r 5 0.94). The new output value, Me value, reﬂected
the global methylation level, had a strong correlation also with the fraction of methylated CpG
sites obtained by bisulphite sequencing (r 5 0.88), and had an accuracy of 71.8 and 83.8%
in detecting completely methylated and unmethylated CGIs. Analysis of gastric cancer cell lines
using the Me value showed that methylation of CGIs in promoters and gene bodies was associated
with low and high, respectively, gene expression. The degree of demethylation of promoter
CGIs after 5-aza-2’-deoxycytidine treatment had no association with that of induction of gene
expression. The Me value was considered to be useful for analysis of intermediate methylation levels
of CGIs.
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1. Introduction
DNA methylation plays a critical role during mam-
malian development and differentiation. Methylation
of a CpG island (CGI) in a gene promoter region has
been known to repress transcription of its down-
stream gene.
1 At the same time, DNA methylation
statuses of CGIs are faithfully inherited upon cell repli-
cation,
2 and are considered to work as a stable switch
of gene transcription.
1 Once a promoter CGI is aber-
rantly methylated, it leads to permanent aberrant
silencing of its downstream gene. Aberrant DNA
methylation is deeply involved in human cancers,
3
and is also likely to be involved in other human-
acquired disorders.
4
There is a great interest in genome-wide analysis of
DNA methylation, and new technologies involving
microarrays and next-generation sequencers are
being developed,
5 replacing traditional techniques.
6
In comparison with techniques using next-generation
sequencers, microarray techniques are cost-effective
and do not need complex bioinformatics. Their
hybridization probes can be prepared by bisulphite
modiﬁcation of unmethylated cytosines, use of
methylation-sensitive restriction enzymes, and afﬁnity
puriﬁcation. The afﬁnity puriﬁcation can be per-
formed by an antibody against 5-methylcytidine or
by methylated DNA binding domains (MBDs). It has
an advantage over the use of restriction enzymes,
since genomic regions analysed by afﬁnity puriﬁcation
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Methylated DNA immunoprecipitation (MeDIP)-
microarray analysis has been used to obtain a high-
resolution whole-genome DNA methylation proﬁle
of various genomes.7–17However, quantitative assess-
ment of intermediate methylation levels has been
hampered by the difﬁculty in appropriate normaliza-
tion. Methylation levels have a unique distribution
pattern that is essentially different from gene
transcription and is likely to be bimodal.
17,18 Also,
global methylation levels in different samples are
highly variable, and there are few reference genes
that have consistent methylation levels across
various samples. To overcome these issues, two
methods (Batman and MEDME) were recently
developed.
14,16
Batman (Bayesian tool for methylation analysis)
transforms a signal log ratio of an individual probe
to a value of methylation level taking account of the
methylation levels of nearby CpG sites using standard
Bayesian techniques. It is capable of processing data
obtained by microarray and by next-generation
sequencers. The method was validated by bisulphite
sequencing of sperm samples,
14 and its validity in
samples with different global methylation levels
remains to be established. MEDME (modelling exper-
imental data with MeDIP enrichment) weighs signal
log ratios of individual probes using a logistic model
and signals obtained by neighbouring probes and by
using completely methylated DNA samples.
16 Both
Batman and MEDME had good correlation with
methylation levels obtained by bisulphite sequencing
(R
2 ¼ 0.82 and 0.75, respectively). Also, both are
capable of processing data from both CpG-rich and
-poor regions, and this made their conversion algor-
ithm complex as a trade-off.
In this study, we developed a novel output value, the
‘Me value’, that can be calculated from raw output
values, and conﬁrmed that the value had a linear cor-
relation with methylation levels of genomic regions
using samples with various global methylation levels.
The Me value was used to clarify how methylation
of CGIs in various positions against transcription
start sites (TSSs) is associated with gene expression,
and how demethylation of CGIs is associated with
re-expression of genes.
2. Materials and methods
2.1. Cell lines and tissue samples
AGS and KATOIII gastric cancer cell lines were
obtained from the American Type Culture Collection
(Manassas, VA, USA) and the Japanese Collection of
Research Bioresources (Tokyo, Japan), respectively.
HSC39 and HSC57 gastric cancer cell lines were
gifted by Dr K. Yanagihara, National Cancer Center
Research Institute, Tokyo, Japan. Treatment with a
demethylating agent, 5-aza-2’-deoxycytidine (5-aza-
dC, Sigma, St Louis, MO, USA), was performed as in
our previous study (AGS, 3 days, 1 mM).
19 A normal
gastric tissue sample was prepared by pooling
endoscopic biopsy specimens from three healthy
volunteers with informed consents. High-molecular-
weight DNA was extracted by the phenol/chloroform
method with RNase A treatment.
2.2. MeDIP and quantiﬁcation of the number
of immunoprecipitated DNA molecules
Five micrograms of genomic DNA were sonicated
by a VP-5s homogenizer (TAITEC, Saitama, Japan) to
fragment lengths between 200 and 800 bp. The
mode of fragment length was about 300 bp. After
heat denaturation at 958C for 10 min, DNA was incu-
bated with 5 mg antibody against 5-methylcytidine
(Diagnode, Lie ´ge, Belgium) in 1  IP buffer [10 mM
Na-phosphate, pH 7.0, 140 mM NaCl, 0.05% (w/v)
Triton X-100] at 48C overnight. Immune complexes
were collected with Dynabeads Protein A (Invitrogen
Dynal AS, Oslo, Norway), washed with 1  IP buffer
four times, treated with Proteinase K, and puriﬁed
by phenol and chloroform extraction and isopropanol
precipitation.
To assess the fraction of immunoprecipitated (IP)
DNA molecules among that of the total DNA (whole
cell extract DNA, WCE) molecules, the number of IP
and WCE molecules was quantiﬁed by real-time PCR
using SYBR
w Green I (BioWhittaker Molecular
Applications, Rockland, ME, USA) and an iCycler
Thermal Cycler (Bio-Rad Laboratories, Hercules, CA,
USA) as described previously.
20 All primers used in
this study are listed in Supplementary Table S1.
2.3. CGI microarray analysis
Methylation microarray analysis was carried out
using a human CGI oligonucleotide microarray
(Agilent Technologies, Santa Clara, CA, USA) that con-
tained 237 220 probes in or within 95 bp either side
of a CGI and covered 27 800 CGIs with an average
probe spacing of 100 bp. IP from 4.5 mg of sonicated
DNA and 1.0 mg of WCE, without any ampliﬁcation,
were labelled with Cy5 and Cy3, respectively, using
an Agilent Genomic DNA Labeling Kit PLUS (Agilent
Technologies). Labelled DNA was hybridized to the
microarray at 678C for 40 h with constant rotation
(20 rpm), and then scanned with an Agilent
G2565BA microarray scanner (Agilent Technologies).
From the scanned data, signal values of the IP and
WCE were obtained using Feature Extraction Ver.9.1
(Agilent Technologies). These two signal values were
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ratio (IP/WCE), signal log ratio [log2(IP/WCE)], P[X],
and P½  X  were obtained using Agilent G4477AA ChIP
Analytics 1.3 software (Agilent Technologies). The
P[X] and P½  X  values, which are used in chromatin
immunoprecipitation (ChIP)-on-chip analysis to
obtain a binding call,
21–25 were deﬁned as the prob-
ability how the X (  X) value deviates from Gaussian dis-
tribution of X (  X) values of the entire genome of a
sample. Here, the X value for a probe was obtained
as the difference between the IP and the WCE
signals after adjusting the symmetry of its distribution.
The   X value for a probe was calculated as an average X,
taking account of signals for neighbouring probes
(within 1 kb of the probe). In addition, to calculate
signal log ratio in experiments speciﬁcally referred
to, the two signal values were also normalized by
the Median and the Lowess normalization methods.
The microarray results were submitted to the GEO
database (GSE15291).
2.4. Calculation of the Me value
The Me value of each probe (site Me value) was
calculated as Me value ¼ [signal log ratio   (1 2
P½  X ) 2 k]/l þ 0.5. The P½  X  value and signal log ratio
normalized using background subtraction were used
for this formula. The [signal log ratio   (1 2 P½  X )]
value mostly ranged from 0 to 2.6 in this study, and
in general, the distribution depends on the microarray
platform. Accordingly, the constant l was ﬁxed at 2.6
in this study, so that the Me value would be within a
range between 0 and 1. Me values larger than 1
and those smaller than 0, which were occasionally
produced after calculation, were corrected to 1 and
0, respectively. The constant k was calculated as [the
signal log ratio of CGIs that had a 50% fraction of
DNA molecules IP (1.7 in this study) – 0.4], which
equalled to 1.3 in this study. The signal log ratio of
CGIs with 50% methylation depends on the microar-
ray platform, labelling method, and mixture rate of IP
and WCE, but does not need to be changed once
established to suit a protocol.
The Me value was calculated only for probes with
high reliability. To select such probes, ﬁrst, probes
that yielded extremely high signal intensities (5-fold
higher than average) for the WCE (Cy-3) were
excluded. Since the signals obtained for the WCE
should be the same theoretically for all the probes,
extremely high signals were considered to be due to
cross-hybridization. Then, continuity of signal log
ratios of neighbouring probes was enforced. If the
value of a probe was higher than those of neighbour-
ing probes on both sides, it was corrected to their
average because the value was likely to be an error.
In addition, efﬁciency in labelling and hybridization
in each microarray analysis was monitored by the
signal log ratio and the fraction of DNA molecules IP
by MeDIP at 10 probe loci. The data processing for
the Me value was performed by Excel 2007
(Microsoft, Redmond, WA, USA), and the templates
are available upon request.
2.5. Deﬁnitions of genomic regions
The position of each probe against a TSS was deter-
mined using UCSC hg18 (NCBI Build 36.1, March
2006). A single CGI was deﬁned as an assembly of
probes in the CGI microarray with intervals
,500 bp. CGIs were classiﬁed into four categories:
upstream CGIs (within 10 kb upstream of the TSS),
divergent CGIs (within 10 kb upstream of the TSSs
of two genes that are transcribed in opposite direc-
tions), gene body CGIs, and downstream CGIs
(within 10 kb downstream of genes). A CGI spanning
both an upstream region and a gene body was split
into an upstream CGI and a gene body CGI. A putative
promoter region (promoter) was deﬁned as a region
between a TSS, determined by UCSC hg18 (NCBI
Build 36.1, March 2006) and its 200 bp upstream.
According to these deﬁnitions, 34 697 assemblies of
probes were deﬁned as CGIs, and 9624 assemblies
were deﬁned as promoters. Genes with multiple pro-
moters were analysed as different genes because of
their multiple TSSs. CGIs that could not be classiﬁed
by these criteria (4164 CGIs) were omitted from
the following analysis. An average number of probes
that covered a single CGI (or a single promoter) was
6.8 (2.0), and the distribution of the numbers is
shown in Supplementary Fig. S1.
2.6. Expression microarray analysis
Microarray analysis of gene expression was per-
formed using GeneChip (Affymetrix) as described
previously,
19,26 and the signal intensities were nor-
malized, so that the average intensity of all the
genes on a microarray would be 500. The average
signal intensity of all the probes for a gene was used
as its expression level. Genes with signal intensities
of 1000 or more and of 250 or less were deﬁned as
those with high and low expression, respectively.
2.7. Bisulphite treatment, methylation-speciﬁc PCR,
and bisulphite sequencing
Bisulphite modiﬁcation was performed using
BamHI-digested genomic DNA as descried pre-
viously.
26 Methylation-speciﬁc PCR (MSP) was per-
formed using bisulphite-treated DNA as descried
previously.
26 Bisulphite sequencing was performed
after cloning the PCR product (10 clones or more
for each sample). We used the data of methylation
status previously analysed.
19,26–30
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region and CGI (or promoter) using the
microarray data
A methylation level of a genomic region analysed by
quantitative PCR of IP DNA molecules was assessed by
an output value of a probe within the PCR product
and closest to the forward primer, or a probe closest
to the PCR product when no probes were present
within the PCR product. A methylation level of a
region analysed by bisulphite sequencing (200 bp)
was assessed by an output value of a probe in the
centre of the region. This was possible because bisul-
phite sequencing was performed for a region larger
than 100 bp upstream and downstream of a probe,
and methylation statuses of CpG sites within the
200 bp region were scored. A methylation level of a
CGI (or promoter) was assessed by an average of site
Me values of the probes located within the CGI (or
promoter), which was deﬁned as the CGI (or promo-
ter) Me value.
3. Results and discussion
3.1. Assessment of current output values for
methylation levels
We ﬁrst examined whether or not distribution of
the available output values reﬂected the global
methylation levels. The output values analysed were:
(i) the signal log ratio, which is most frequently used
in microarray analysis, (ii) the P[X] value, and (iii)
P½  X  value, which is often used in ChIP-on-chip analy-
sis. Their distribution was analysed in two samples, a
cell line (AGS) with frequent CGI methylation
26 and
the same cell line after treatment with 5-aza-dC.
Our previous study showed that AGS after 5-aza-dC
treatment has demethylation of at least 421 promo-
ter CGIs,
19 and its global methylation level was
expected to shift towards unmethylated ranges.
Among the three values, the signal log ratio showed
such a shift (Fig. 1A). On the other hand, the P[X]
and P½  X  values did not show such a shift (Fig. 1B
and C).
Next, a linear correlation with methylation level,
represented here by the fraction of DNA molecules
IP by the anti-5-methylcytidine antibody, was exam-
ined for individual output values using 31 genomic
regions located within various CGIs. In addition to
the three output values, (iv) the signal ratio (back-
ground subtraction normalization), (v) the signal log
ratio with Median normalization, and (vi) the signal
log ratio with the Lowess normalization were ana-
lysed. Although P½  X  gave a correlation coefﬁcient of
20.91 (r, Pearson’s), the absolute values of corre-
lation coefﬁcients using other output values were
smaller than 0.72 (Supplementary Fig. S2). Median
and Lowess normalization did not improve the linear
correlation.
3.2. Development of a novel output value ‘Me value’
To improve the linearity of the signal log ratio, which
reﬂected the global methylation levels, P½  X , which had
a strong linear correlation, was used as a coefﬁcient to
multiply it. Because P½  X  showed an inverse correlation,
(1 2 P½  X ) was used as a coefﬁcient to multiply the
signal log ratio ‘¼(1 2 P½  X )   signal log ratio’. This
value showed a higher correlation coefﬁcient (0.93)
than the other output values (Supplementary Fig.
S2). This value was scaled to a value with a minimum
value of 0 and a maximum value of 1 using the con-
stants in Section 2, and the scaled output value was
designated as the ‘Me value’. The Me value had the
largest correlation coefﬁcient (0.94) among all of the
output values analysed. The distribution of the Me
value reﬂected the global methylation levels by
showing a shift towards smaller values after demethy-
lation (Fig. 1D).
The Me value was generated taking advantage of
the signal log ratio and P½  X . The signal log ratio was
not quantitative but reﬂected the global methylation
levels. On the other hand, P½  X  had a high linear corre-
lation with the fraction of DNA molecules IP by the
anti-5-methylcytidine antibody. The P½  X  value is
obtained as a probability value that takes account of
neighbouring probes, and reﬂects the methylation
level of a small local region. Since the vast majority
of CpG sites within a CGI are (un)methylated when
the CGI is (un)methylated,
31 the P½  X  value was con-
sidered to have an advantage in faithful reﬂection of
the local methylation status.
3.3. High accuracy of MeDIP-CGI microarray with Me
value
In addition to the linear correlation between the Me
value and the fraction of DNA molecules IP, a linear
correlation between the Me value and the fraction
of methylated CpG sites was analysed. Fractions of
methylated CpG sites of 11 genomic regions (each
200 bp) with a variety of methylation levels were
obtained by bisulphite sequencing in four different
cell lines with different global methylation levels
26
(44 values in total). The Me value was obtained for
a probe (site Me value) in the centre of the genomic
region analysed. A strong correlation (r ¼ 0.88,
Fig. 2) was observed. The correlation was stronger
than any of those obtained by the other output
values. When the analysis was limited to genomic
regions with intermediate Me values, the correlation
coefﬁcients were 0.75 (Me value: 0.1–0.9); 0.53
(0.2–0.8); 0.47 (0.3–0.7); and 0.19 (0.4–0.6).
These data further supported that a site Me value
278 Me Value in MeDIP-CGI Microarray [Vol. 16,reﬂects a methylation level of a small genomic region
(200 bp), even if it is within an intermediate range,
and that the Me value is useful for the analysis of
various biological samples, such as tissue samples.
Cancer tissues sometimes show mixtures of methyl-
ated and unmethylated CpG sites on the same DNA
molecule (mosaic pattern). Even in this case, multiple
CpG sites are usually located within the average size of
shearing DNA (300 bp) because there are 9–53 CpG
sites in 300 bp regions of promoter CGIs.
20 If two or
more CpG sites are methylated, such DNA molecules
are reported to be efﬁciently IP.
9 Therefore, it is
expected that, for most CGIs, the Me value will work
even in samples with mosaic pattern methylation,
such as cancer tissues.
Next, detection of completely methylated and
unmethylated statuses of CGIs was attempted. Using
output values other than the Me value, this has
been achieved by optimizing cut-off values depending
upon samples because their global methylation levels
were highly variable. Since the Me value well reﬂected
the global methylation levels, we tried to use cut-off
CGI Me values common to different samples.
Methylation statuses of 113 CGIs in four cell lines
with different global methylation levels
26 (452
values in total) were scored using various cut-off CGI
Me values. A high speciﬁcity with little compromise
of sensitivity was achieved with the cut-off values of
0.6 and 0.4 for highly methylated and unmethylated
CGIs, respectively (Supplementary Fig. S3). Accuracies
Figure 1. Distribution of methylation levels assessed by the available output values and the Me value in a gastric cancer cell line, AGS, and
the same cell line after 5-aza-dC treatment. The analysis was performed for the signal log ratio with background subtraction
normalization (A), the P[X] value (B), the P½  X  value (C), and the Me value (D). Lines between the two bar graphs indicate values of
individual probes (randomly selected representative 20 values). Distributions of the signal log ratio and the Me value reﬂected the
global methylation level, as shown by their shift towards smaller values in cells with 5-aza-dC treatment. In contrast, those of the
P[X] and P½  X  values did not show the shift.
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cut-off values were 71.8 and 83.8%, respectively
(Table 1). Since these cut-off CGI Me values worked
in the four samples with different global methylation
levels, Me values of 0.6 and 0.4 were considered
to be suitable to identify highly methylated and
unmethylated CGIs, respectively, with reasonable
accuracies.
These data showed that, for quantiﬁcation of
methylation levels, the Me value had linearity similar
to Batman and MEDME.
14,16 Although samples ana-
lysed were different, the coefﬁcient of determination
Figure 2. Correlation between an output value and the fraction of methylated CpG sites by bisulphite sequencing. Forty samples with
variable methylation levels (11 loci in four cell lines) were analysed by bisulphite sequencing, and the fraction of methylated CpG
sites among all the CpG sites within 200 bp of the microarray probes was obtained. The numbers of CpG sites in this region ranged
from 7 to 21. The Me value had a linear correlation with the fraction (r ¼ 0.88, Pearson’s correlation coefﬁcient).
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2, Pearson’s) obtained by the Me value was 0.77,
being in the same range as Batman (0.82) and
MEDME (0.75). The linearity of the Me value was vali-
dated also using four samples with different global
methylation levels, which has not been done with
Batman (one sample) and MEDME (two samples).
Further, the CGI Me value enabled us to score comple-
tely methylated and unmethylated statuses of CGIs in
samples with variable global methylation levels using
common cut-off values. It is also of note that the Me
value can be conveniently calculated using a spread-
sheet and a commercially available software, such as
Excel (Microsoft).
3.4. Application of the Me value to analysis of the
association between CGI methylation and gene
expression
Using the Me value, methylation proﬁles of CGIs
and promoters were analysed in four gastric cancer
cell lines, AGS cells after 5-aza-dC treatment, and
one normal gastric tissue sample (a pool of four
samples from four individuals). CGIs (promoters)
with CGI (promoter) Me values more than 0.6 were
classiﬁed as ‘methylated’. Of the 30 533 CGIs ana-
lysed, 3768–7310 CGIs were methylated in the
cancer cell lines, and 3393 CGIs were methylated
in the normal sample (Table 2). However, methyl-
ation was infrequent in promoters (Table 2,
Supplementary Fig. S4A and B). The ratio of methyl-
ated promoters in cancer cell lines (6.7–12.5%) was
in accordance with that in a previous report (10.9%
in lung cancer cell lines).
32 The difference between
overall CGIs and promoters was clearer in the
normal gastric tissue than in the human gastric
cancer cell lines. Interestingly, CGIs in the vicinity of
the LINE and SINE repetitive elements had lower Me
values than those further away from them in cancer
cell lines (Supplementary Fig. S4C and D). A small
peak was observed at 300 bp from SINE, and CGIs
closer to SINE and LINE were less methylated than
those further apart from SINE and LINE. There is a
possibility that a boundary function of these repeti-
tive elements prevents methylation beyond the
boundary spread across into CGIs. Actually, SINE is
reported to have binding sites for the TFIIIC transcrip-
tion factor, and to protect promoter CGIs from repres-
sive chromatin modiﬁcations.
33
The numbers of methylated CGIs were larger in AGS
and KATOIII than in HSC39 and HSC57, which was in
accordance with our previous ﬁndings.
26 The differ-
ence among the four cell lines was observed not
only at the overall genome level but also on individual
chromosomes (Supplementary Fig. S5). In contrast,
the numbers of methylated promoters had the same
difference at the overall genome level, but some dis-
tortions were present on speciﬁc chromosomes. For
example, HSC39 had the largest numbers of methyl-
ated promoters on chromosomes 15, 18, and 22,
and HSC57 had the largest number on chromosome
21. This result suggested that promoters have
unique mechanisms to be methylated in cancer
cells, such as functional selection of a cell with
methylation of speciﬁc promoters.
Gene expression proﬁles were also obtained by
expression microarray analysis of the same four
cancer cell lines and the normal gastric tissue
sample. When genes were classiﬁed by their
expression levels, genes with high expression had
lower methylation levels in their promoters than
Table 1. Comparison between methylation statuses determined using the CGI Me value and those by MSP
MSP MeDIP-CGI microarray AGS HSC39 HSC57 KATOIII Total
Methylated Highly methylated 64 17 12 36 129
Moderately methylated 29 13 6 23 71
Unmethylated 4 3682 1
Unmethylated Highly methylated 1 6741 8
Moderately methylated 2 8 11 4 25
Unmethylated 11 56 61 21 149
Methylated/unmethylated Highly methylated 0 4581 7
Moderately methylated 1 4251 2
Unmethylated 1 2 2 4 9
Not ampliﬁed by MSP 0 0 1 0 1
Methylated Sensitivity 0.660 0.515 0.500 0.537 0.584
Speciﬁcity 0.938 0.875 0.864 0.739 0.848
Accuracy 0.699 0.770 0.786 0.619 0.718
Unmethylated Sensitivity 0.786 0.800 0.772 0.724 0.776
Speciﬁcity 0.949 0.884 0.758 0.857 0.884
Accuracy 0.929 0.832 0.768 0.823 0.838
Using 113 CGIs, we compared methylation statuses determined using the Me value and those by MSP.
Methylated/unmethylated, both methylated and unmethylated DNA molecules were detected by MSP.
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When genes were classiﬁed by methylation levels
(unmethylated, moderately methylated, and highly
methylated), genes with high methylation in their
promoters had lower expression than those with low
methylation (left panel in Fig. 3B). In contrast, genes
with high methylation in their gene bodies (5 kb or
more downstream of TSSs) had slightly, but signiﬁ-
cantly, higher expression levels (right panel). These
results clearly showed that methylation of gene
body CGIs was associated with increased gene
expression, as in previous reports.
34–37 Finally,
genes with low expression in normal gastric tissue
had higher methylation levels of promoters in
cancer cell lines (Supplementary Fig. S6). This result
was in line with the fact that genes with low
expression are susceptible to DNA methylation.
20,38,39
3.5. Application of the Me value to analyse the effect of
a demethylating agent
Treatment of cells with 5-aza-dC induces demethy-
lation of various CGIs, but the degree depending
upon their positions against TSSs has not been
clariﬁed. The relationship between the degree of
demethylation of promoters and that of expression
induction has not been clariﬁed, either. To address
these two issues, we analysed methylation and gene
expression levels in AGS before and after 5-aza-dC
treatment.
Demethylation of the genes with methylated CGIs
or promoters (Me value . 0.6) before 5-aza-dC treat-
ment was analysed. The average degree of demethyla-
tion was not inﬂuenced by the positions of CGIs
against their TSS (Fig. 4A), whereas the degree of
demethylation of individual CGIs was highly variable
(representative genes in Fig. 4B). The average degree
was not inﬂuenced by the distance between a CGI
and repetitive elements (LINE, SINE), either (data
not shown). There was no correlation (r ¼ 0.12,
Fig. 4C) between the degree of demethylation of pro-
moters (decrease of Me value in MeDIP-CGI microar-
ray) and that of induction of gene expression (fold
increase of signal log ratio in expression microarray
analysis). The majority of genes with methylation
of their promoters showed little or no increase of
expression after 5-aza-dC treatment. The number of
methylated promoters identiﬁed by MeDIP-microar-
ray analysis was much larger than that of genes ident-
iﬁed as silenced by expression microarray analysis
after 5-aza-dC treatment (Table 3).
These results showed that expression cannot be
induced for the majority of genes with methylation
of their promoters even with a demethylating agent,
possibly due to the lack of transcriptional factors or
the presence of inactive histone modiﬁcations.
Genes with low transcription tend to become methyl-
ated,
20,38,39 and such genes are unlikely to be
expressed even if the methylation is removed.
Caution is necessary when the relationship between
methylation of the promoter and the expression of a
gene is interpreted.
3.6. Application of the Me value in future studies
The differential role of DNA methylation in promo-
ters and gene bodies and the lack of association
between the degree of demethylation of promoters
and that of induction of gene expression were
clearly shown due to the accuracy of the Me value.
We here focused on CGIs using a CGI microarray.
Roles of methylation of CpG-poor genomic regions
Table 2. DNA methylation proﬁles of CGIs according to their positions against TSSs obtained by MeDIP-CGI microarray
Total
number
analysed
Number of methylated CpG islands and promoters
AGS HSC39 HSC57 KATOIII AGS þ 5-aza-
dC (1 mM)
Normal gastric
tissue
CpG islands
All CGI 30 533 7310 (23.9%) 3768 (12.3%) 4663 (15.3%) 6460 (21.2%) 4 (0.0%) 3393 (11.1%)
Upstream 10 709 1911 (17.8%) 937 (8.7%) 794 (7.4%) 1556 (14.5%) 1 (0.0%) 260 (2.4%)
Gene body
(þ1t oþ1k )
10 654 1607 (15.1%) 867 (8.1%) 665 (6.2%) 1328 (12.5%) 0 (0.0%) 194 (1.8%)
Gene body
(þ1t oþ5k )
2050 694 (47.0%) 508 (24.8%) 598 (29.2%) 809 (39.5%) 1 (0.0%) 353 (17.2%)
Gene body (more
than þ5k )
4431 2438 (55.0%) 1099 (24.8%) 2171 (49.0%) 2155 (48.6%) 2 (0.0%) 2360 (53.3%)
Downstream 1186 561 (47.3%) 310 (26.1%) 376 (31.7%) 509 (42.9%) 0 (0.0%) 216 (18.2%)
Divergent 1503 99 (6.6%) 47 (3.1%) 59 (3.9%) 103 (6.9%) 0 (0.0%) 10 (0.7%)
Promoters 9624 1205 (12.5%) 792 (8.2%) 641 (6.7%) 1142 (11.9%) 3 (0.0%) 113 (1.2%)
Probes 237 202 70 027 (29.5%) 43 825 (18.5%) 48 292 (20.4%) 65 192 (27.5%) 723 (0.3%) 27 017 (11.4%)
Deﬁnitions of the CGI positions are described in Section 2.
282 Me Value in MeDIP-CGI Microarray [Vol. 16,in genome regulation are not as clear as those of
CGIs,
10,40 and focusing on CpG-rich regions is advan-
tageous to isolate genes of interest. Also, the collec-
tion efﬁciency of methylated DNA by MeDIP or MBD
is low in CpG-poor genomic regions,
7,9,41 and analysis
of both CpG-poor and -rich regions leads to a compli-
cated algorithm for normalization. The selective
analysis of CGIs enabled us to develop a simple, but
reliable output value.
The use of MeDIP allowed us to analyse methylation
levels of any genomic regions regardless of the
presence of restriction sites, and we were able to
focus on promoters in some part of this study. We
did not amplify the IP DNA during preparation of
hybridization probes to avoid any ampliﬁcation bias,
and this was enabled by the use of a microarray plat-
form with a high sensitivity and low signal/noise ratio.
Under these optimal conditions, we achieved a high
reproducibility (r ¼ 0.98) and simplicity for the quan-
titative methylation microarray analysis.
In conclusion, we developed a new output value
for microarray analysis suitable for quantitative
Figure 3. Association between DNA methylation level and gene expression. (A) Average methylation levels (site Me values) of genes with
high and low expression. Genes with low expression (dashed line) showed signiﬁcantly higher methylation levels than those with high
expression (solid line) in positions close to TSSs. (B) Gene expression levels according to methylation statuses of the promoters (left
panel) and gene bodies (right panel). Genes were classiﬁed into unmethylated (CGI Me value ,0.4, dotted line), moderately
methylated (0.4   CGI Me value   0.6, dashed line), and highly methylated (CGI Me value .0.6, solid line). Methylation of
promoters was strongly associated with low expression (P ¼ 8   10
2203 in AGS, t-test of expression of methylated genes and
unmethylated genes), and methylation of CGIs in gene bodies was associated with higher expression (P ¼ 6   10
24 in AGS).
No. 5] S. Yamashita et al. 283assessment of DNA methylation levels. The Me value
will be useful in genome-wide screening using hetero-
geneous samples.
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